Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul Genuth

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Diabetes|March 16, 2007
The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications TrialJohn M Lachin, Saul Genuth, David M Nathan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 9, 2010
Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT)Elizabeth F O Kern, Penny Erhard, Wanjie Sun, et al.
Diabetes|January 29, 2008
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisitedJohn M Lachin, Saul Genuth, David M Nathan, et al.
The New England Journal of Medicine|February 10, 2000
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy, John M Lachin, Saul Genuth, et al.
Clinical Chemistry and Laboratory Medicine|June 22, 2013
Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complicationsVincent M Monnier, Wanjie Sun, David R Sell, et al.
Diabetes Care|March 1, 2005
The burden of treatment failure in type 2 diabetes: response to Brown et alDenise G Simons-Morton, Saul Genuth, Robert P Byington, et al.
Annals of Internal Medicine|April 20, 2011
Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trialsFaramarz Ismail-Beigi, Etie Moghissi, Margaret Tiktin, et al.
Diabetes|September 5, 2014
Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetesSaul Genuth, Wanjie Sun, Patricia Cleary, et al.
Diabetes Care|December 28, 2002
Implications of the United kingdom prospective diabetes studySaul Genuth, Richard Eastman, Richard Kahn, et al.
Cardiovascular Diabetology|October 11, 2015
Erratum to: Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetesVincent M Monnier, Wanjie Sun, Xiaoyu Gao, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Diabetes|March 16, 2007
The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications TrialJohn M Lachin, Saul Genuth, David M Nathan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 9, 2010
Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT)Elizabeth F O Kern, Penny Erhard, Wanjie Sun, et al.
Diabetes|January 29, 2008
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisitedJohn M Lachin, Saul Genuth, David M Nathan, et al.
The New England Journal of Medicine|February 10, 2000
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy, John M Lachin, Saul Genuth, et al.
Clinical Chemistry and Laboratory Medicine|June 22, 2013
Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complicationsVincent M Monnier, Wanjie Sun, David R Sell, et al.
Diabetes Care|March 1, 2005
The burden of treatment failure in type 2 diabetes: response to Brown et alDenise G Simons-Morton, Saul Genuth, Robert P Byington, et al.
Annals of Internal Medicine|April 20, 2011
Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trialsFaramarz Ismail-Beigi, Etie Moghissi, Margaret Tiktin, et al.
Diabetes|September 5, 2014
Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetesSaul Genuth, Wanjie Sun, Patricia Cleary, et al.
Diabetes Care|December 28, 2002
Implications of the United kingdom prospective diabetes studySaul Genuth, Richard Eastman, Richard Kahn, et al.
Cardiovascular Diabetology|October 11, 2015
Erratum to: Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetesVincent M Monnier, Wanjie Sun, Xiaoyu Gao, et al.
Pageof 6